Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Abstract

There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (n = 2) and mast cell activation syndrome (n = 2). We show that this molecule reduces the long-term survival of primary human mast cells, interferes with lysosome function and leads to the accumulation of non-functional tryptase in the mast cell granules. Furthermore, hydroxychloroquine decreases the production of pro-inflammatory mediators.

Keywords: Hydroxychloroquine; Mast cell activation diseases; Mast cell activation syndrome; Mast cells; Mastocytosis.